Clinical Trial Detail

NCT ID NCT04134260
Title Testing the Addition of the Drugs, Apalutamide and Abiraterone Acetate With Prednisone, to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer
Recruitment Recruiting
Gender male
Phase Phase III
Variant Requirements No
Sponsors NRG Oncology
Indications

prostate adenocarcinoma

Therapies

Abiraterone + Apalutamide + Prednisone

Age Groups: adult senior

No variant requirements are available.